<unk> -nucleoside reverse-transcriptase inhibitors (NNRTIs) are antiretroviral drugs used in the treatment of human immunodeficiency virus (HIV). NNRTIs inhibit reverse<unk>  (RT), an enzyme that controls the replication of the genetic material of HIV. RT is one of the most popular targets in the field of antiretroviral drug<unk> . Discovery and<unk>  of NNRTIs began in the late 1980s and in the end of 2009 four NNRTI had been approved by regulatory authorities and several others were undergoing clinical<unk> . Drug resistance develops quickly if NNRTIs are administered as monotherapy and therefore NNRTIs are always given as part of combination therapy, the highly active antiretroviral therapy (HAART).
Discovery and development of non-nucleoside reverse-transcriptase inhibitors
Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors
Zinc finger nuclease treatment of HIV
Vectors in gene therapy
Innate resistance to HIV
Cancer vaccine targeting CD4+ T cells
Targeted covalent inhibitors
Individualized cancer immunotherapy